Key Insights

Highlights

Treatment Research

2 treatments under study, led by Cergenx Wave

Research Leaders

13 sponsors active, led by Saitama Medical University

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Not Yet Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07857070Not Yet Recruiting

Newborn Brain Assessment - CergenX Wave

NCT02455830UnknownPrimary

Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy

Showing all 2 trials

Research Network

Common Treatments

  • Cergenx Wave1
  • Autologous Cord Blood Cell Therapy1

Active Sponsors

  • Saitama Medical University1
  • Osaka City University1
  • Tokyo University1
  • CergenX Limited1
  • Yodogawa Christian Hospital1

Top Investigators

Related Conditions

  • Neonatal Encephalopathy1
  • Neonatal Encephalopathy Unspecified1

Activity Timeline